Drug Sponsors

AbbVie Innovation Center opens at the University of Illinois Research Park

Thursday, January 22, 2015 12:18 PM

AbbVie, a global research-based biopharmaceutical company based in North Chicago, Ill., has opened the AbbVie Innovation Center on campus at the University of Illinois Research Park in Urbana-Champaign.

More... »

Quest Diagnostics

SV Bio renames itself Lifecode, launches oncology assay

Thursday, January 22, 2015 12:17 PM

Silicon Valley Biosystems (SV Bio) has changed its name to Lifecode. The new name is consistent with the company's mission to improve the lives of patients by providing concise, accurate and actionable molecular information. Lifecode also has released its flagship next generation sequencing (NGS)-based oncology assay, the Pan Cancer Somatic Panel (PCSP), to a select group of physicians nationwide in advance of a broad launch later this spring.

More... »


Roche acquires Trophos to expand neuromuscular disease portfolio

Wednesday, January 21, 2015 01:00 PM

Roche has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. The company has developed a proprietary cholesterol-oxime based chemistry platform. Trophos's mitochondrial targeted compounds enhance the function and survival of stressed cells by preventing mitochondrial permeability transition, a key determinant of cell death or survival.

More... »

20 life sciences, IT organizations invest in tranSMART Foundation

Thursday, January 15, 2015 12:55 PM

The tranSMART Foundation, a nonprofit organization headquartered in Wakefield, Mass., providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, said 20 life sciences and technology organizations have made substantial commitments by joining its membership program.

More... »

Tekmira Pharmaceuticals, OnCore Biopharma to merge

Wednesday, January 14, 2015 12:42 PM

Tekmira Pharmaceuticals, based in Vancouver, a developer of RNA interference (RNAi) therapeutics, and OnCore Biopharma, a Doylestown, Pa.-based biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection, have agreed to merge to create a new global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.

More... »

Regado Biosciences, Tobira Therapeutics to merge

Wednesday, January 14, 2015 12:34 PM

Regado Biosciences, a development stage biotechnology company based in Basking Ridge, N.J., and Tobira Therapeutics, a clinical-stage biopharmaceutical company in South San Francisco, have agreed to merge. Privately held Tobira will merge with a wholly-owned subsidiary of Regado in an all-stock transaction. The merger will create a company focused on the development of novel treatments for liver and inflammatory diseases.

More... »

Qiagen acquires Enzymatics’ Enzyme Solutions Unit

Tuesday, January 13, 2015 10:30 AM

Qiagen, a Netherlands-based holding company, has acquired the Enzyme Solutions Unit of Enzymatics, a developer, manufacturer and OEM supplier of enzymes essential to driving the adoption of Next-Generation Sequencing (NGS) and other genetic analysis technologies in life sciences research and clinical healthcare.

More... »

Biogen Idec to acquire Convergence Pharmaceuticals, expands neuropathic pain portfolio

Tuesday, January 13, 2015 09:30 AM

Biogen Idec has agreed to acquire U.K.-based Convergence Pharmaceuticals, a clinical-stage biopharmaceutical company with an innovative portfolio of ion channel-modulating product candidates for neuropathic pain. Biogen Idec plans to leverage Convergence’s experience in chronic pain research and clinical development to accelerate the growth of its pain portfolio.

More... »

Roche to acquire majority ownership of Foundation Medicine

Monday, January 12, 2015 02:44 PM

Foundation Medicine (FMI), based in Cambridge, Mass., and Roche will enter into a broad strategic collaboration to further advance Foundation Medicine's position in molecular information and genomic analysis while providing Roche a unique opportunity to optimize the identification and development of novel treatment options for cancer patients. Roche also will acquire majority ownership of Foundation Medicine.

More... »

Shire to acquire NPS Pharma for $5.2 billion

Monday, January 12, 2015 02:38 PM

Dublin, Ireland-based Shire and NPS Pharmaceuticals have entered into a merger agreement, under which Shire will acquire all outstanding shares of NPS Pharma for $46 per share in cash, for a total consideration of approximately $5.2 billion.

More... »

CenterWatch
CWWeekly

April 27

Doctors, patients in the U.S. and U.K. agree: Mobile health apps are good for our health

AARP teams with Georgia Tech's HomeLab, Pfizer and UnitedHealthcare to test wearables with consumers 50+

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs